

# Peter E Penson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/843671/publications.pdf>

Version: 2024-02-01

111  
papers

2,517  
citations

186265

28  
h-index

243625

44  
g-index

113  
all docs

113  
docs citations

113  
times ranked

3167  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence of statin intolerance: a meta-analysis. <i>European Heart Journal</i> , 2022, 43, 3213-3223.	2.2	151
2	The sirtuin family members SIRT1, SIRT3 and SIRT6: Their role in vascular biology and atherogenesis. <i>Atherosclerosis</i> , 2017, 265, 275-282.	0.8	144
3	Introducing the “Drucebo” effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018, 9, 1023-1033.	7.3	84
4	The role of nutraceuticals in the prevention of cardiovascular disease. <i>Cardiovascular Diagnosis and Therapy</i> , 2017, 67, S21-S31.	1.7	81
5	Inclisiran “New hope in the management of lipid disorders?”. <i>Journal of Clinical Lipidology</i> , 2020, 14, 16-27.	1.5	80
6	LDL-C: lower is better for longer “even at low risk. <i>BMC Medicine</i> , 2020, 18, 320.	5.5	78
7	The impact of type of dietary protein, animal versus vegetable, in modifying cardiometabolic risk factors: A position paper from the International Lipid Expert Panel (ILEP). <i>Clinical Nutrition</i> , 2021, 40, 255-276.	5.0	75
8	Effects of carbohydrate-restricted diets on low-density lipoprotein cholesterol levels in overweight and obese adults: a systematic review and meta-analysis. <i>Nutrition Reviews</i> , 2019, 77, 161-180.	5.8	71
9	Associations between very low concentrations of low density lipoprotein cholesterol, high sensitivity C-reactive protein, and health outcomes in the Reasons for Geographical and Racial Differences in Stroke (REGARDS) study. <i>European Heart Journal</i> , 2018, 39, 3641-3653.	2.2	69
10	Brief recommendations on the management of adult patients with familial hypercholesterolemia during the COVID-19 pandemic. <i>Pharmacological Research</i> , 2020, 158, 104891.	7.1	62
11	Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP). <i>Pharmacological Research</i> , 2021, 166, 105499.	7.1	62
12	Does vitamin D supplementation alter plasma adipokines concentrations? A systematic review and meta-analysis of randomized controlled trials. <i>Pharmacological Research</i> , 2016, 107, 360-371.	7.1	61
13	The effects of cinnamon supplementation on blood lipid concentrations: A systematic review and meta-analysis. <i>Journal of Clinical Lipidology</i> , 2017, 11, 1393-1406.	1.5	60
14	Statin-Induced Nitric Oxide Signaling: Mechanisms and Therapeutic Implications. <i>Journal of Clinical Medicine</i> , 2019, 8, 2051.	2.4	60
15	Association of types of dietary fats and all-cause and cause-specific mortality: A prospective cohort study and meta-analysis of prospective studies with 1,164,029 participants. <i>Clinical Nutrition</i> , 2020, 39, 3677-3686.	5.0	52
16	What have we learned about lipids and cardiovascular risk from PCSK9 inhibitor outcome trials: ODYSSEY and FOURIER?. <i>Cardiovascular Research</i> , 2019, 115, e26-e31.	3.8	46
17	Evidence-based assessment of lipoprotein(a) as a risk biomarker for cardiovascular diseases “ Some answers and still many questions. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2016, 53, 370-378.	6.1	41
18	Evaluating bempedoic acid for the treatment of hyperlipidaemia. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 251-259.	4.1	40

#	ARTICLE	IF	CITATIONS
19	Effects of morning vs evening statin administration on lipid profile: A systematic review and meta-analysis. <i>Journal of Clinical Lipidology</i> , 2017, 11, 972-985.e9.	1.5	40
20	Commentary: Statins, COVID-19, and coronary artery disease: killing two birds with one stone. <i>Metabolism: Clinical and Experimental</i> , 2020, 113, 154375.	3.4	40
21	Impact of nutraceuticals on markers of systemic inflammation: Potential relevance to cardiovascular diseases – A position paper from the International Lipid Expert Panel (ILEP). <i>Progress in Cardiovascular Diseases</i> , 2021, 67, 40-52.	3.1	39
22	Intake of Caffeine and Its Association with Physical and Mental Health Status among University Students in Bahrain. <i>Foods</i> , 2020, 9, 473.	4.3	36
23	What do we know about the role of lipoprotein(a) in atherogenesis 57 years after its discovery?. <i>Progress in Cardiovascular Diseases</i> , 2020, 63, 219-227.	3.1	35
24	Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP). <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2022, 13, 1596-1622.	7.3	35
25	Associations between cardiovascular disease, cancer, and very low high-density lipoprotein cholesterol in the REasons for Geographical and Racial Differences in Stroke (REGARDS) study. <i>Cardiovascular Research</i> , 2019, 115, 204-212.	3.8	34
26	Regulatory T cells: Possible mediators for the anti-inflammatory action of statins. <i>Pharmacological Research</i> , 2019, 149, 104469.	7.1	32
27	Effects of pentoxifylline on inflammatory markers and blood pressure. <i>Journal of Hypertension</i> , 2016, 34, 2318-2329.	0.5	31
28	Statins as anti-pyrototic agents. <i>Archives of Medical Science</i> , 2021, 17, 1414-1417.	0.9	31
29	Association between telomere length and complete blood count in US adults. <i>Archives of Medical Science</i> , 2017, 3, 601-605.	0.9	30
30	The Effects of Tamoxifen on Plasma Lipoprotein(a) Concentrations: Systematic Review and Meta-Analysis. <i>Drugs</i> , 2017, 77, 1187-1197.	10.9	29
31	The Role of Protein SUMOylation in the Pathogenesis of Atherosclerosis. <i>Journal of Clinical Medicine</i> , 2019, 8, 1856.	2.4	27
32	A new approach to the diagnosis and treatment of atherosclerosis: the era of the liposome. <i>Drug Discovery Today</i> , 2020, 25, 58-72.	6.4	27
33	Nocebo/drucebo effect in statin-intolerant patients: an attempt at recommendations. <i>European Heart Journal</i> , 2021, 42, 4787-4788.	2.2	27
34	Statins and LDL-C in Secondary Prevention – So Much Progress, So Far to Go. <i>JAMA Network Open</i> , 2020, 3, e2025675.	5.9	27
35	Natural compounds as anti-atherogenic agents: Clinical evidence for improved cardiovascular outcomes. <i>Atherosclerosis</i> , 2021, 316, 58-65.	0.8	26
36	Bioresorbable scaffold – A magic bullet for the treatment of coronary artery disease?. <i>International Journal of Cardiology</i> , 2016, 215, 47-59.	1.7	24

#	ARTICLE	IF	CITATIONS
37	Lipid-lowering therapies: Better together. <i>Atherosclerosis</i> , 2021, 320, 86-88.	0.8	23
38	Effects of statins on myocarditis: A review of underlying molecular mechanisms. <i>Progress in Cardiovascular Diseases</i> , 2021, 67, 53-64.	3.1	23
39	How much should LDL cholesterol be lowered in secondary prevention? Clinical efficacy and safety in the era of PCSK9 inhibitors. <i>Progress in Cardiovascular Diseases</i> , 2021, 67, 65-74.	3.1	23
40	The interaction of <i>Helicobacter pylori</i> with cancer immunomodulatory stromal cells: New insight into gastric cancer pathogenesis. <i>Seminars in Cancer Biology</i> , 2022, 86, 951-959.	9.6	22
41	The effect of statins on cardiovascular outcomes by smoking status: A systematic review and meta-analysis of randomized controlled trials. <i>Pharmacological Research</i> , 2017, 122, 105-117.	7.1	21
42	A Systematic Review of Published Physiologically-based Kinetic Models and an Assessment of their Chemical Space Coverage. <i>ATLA Alternatives To Laboratory Animals</i> , 2021, 49, 197-208.	1.0	20
43	The roles of alpha- and beta-adrenoceptor stimulation in myocardial ischaemia. <i>Autonomic and Autacoid Pharmacology</i> , 2004, 24, 87-93.	0.5	19
44	Vasopressors for cardiopulmonary resuscitation. , 2007, 115, 37-55.		19
45	Relationship between long noncoding RNAs and physiological risk factors of cardiovascular disease. <i>Journal of Clinical Lipidology</i> , 2017, 11, 617-623.	1.5	19
46	Postmarketing nutriviigilance safety profile: a line of dietary food supplements containing red yeast rice for dyslipidemia. <i>Archives of Medical Science</i> , 2021, 17, 856-863.	0.9	19
47	Risk-factors associated with extremely high cardiovascular risk of mid- and long-term mortality following myocardial infarction: Analysis of the Hyperlipidaemia Therapy in tERtiary Cardiological cEnTer (TERCET) registry. <i>Atherosclerosis</i> , 2021, 333, 16-23.	0.8	19
48	RNA Silencing in the Management of Dyslipidemias. <i>Current Atherosclerosis Reports</i> , 2021, 23, 69.	4.8	19
49	Does coffee consumption alter plasma lipoprotein(a) concentrations? A systematic review. <i>Critical Reviews in Food Science and Nutrition</i> , 2018, 58, 1706-1714.	10.3	18
50	Worldwide Dyslipidemia Guidelines. <i>Current Cardiovascular Risk Reports</i> , 2019, 13, 1.	2.0	17
51	Application of PLGA nano/microparticle delivery systems for immunomodulation and prevention of allotransplant rejection. <i>Expert Opinion on Drug Delivery</i> , 2020, 17, 767-780.	5.0	17
52	Statin therapy in athletes and patients performing regular intense exercise – Position paper from the International Lipid Expert Panel (ILEP). <i>Pharmacological Research</i> , 2020, 155, 104719.	7.1	17
53	Efficacy and safety of colchicine in patients with coronary artery disease: A systematic review and meta-analysis of randomized controlled trials. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 1520-1528.	2.4	17
54	Embracing the polypill as a cardiovascular therapeutic: is this the best strategy?. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1857-1865.	1.8	16

#	ARTICLE	IF	CITATIONS
55	Liposome Circulation Time is Prolonged by CD47 Coating. <i>Protein and Peptide Letters</i> , 2020, 27, 1029-1037.	0.9	16
56	Statins and Lp(a): do not make perfect the enemy of excellent. <i>European Heart Journal</i> , 2020, 41, 190-191.	2.2	15
57	The Role of Nutraceuticals in the Optimization of Lipid-Lowering Therapy in High-Risk Patients with Dyslipidaemia. <i>Current Atherosclerosis Reports</i> , 2020, 22, 67.	4.8	15
58	Potential Benefits of Phytochemicals for Abdominal Aortic Aneurysm. <i>Current Medicinal Chemistry</i> , 2021, 28, 8595-8607.	2.4	14
59	Drucebo effect – the challenge we should all definitely face!. <i>Archives of Medical Science</i> , 2021, 17, 542-543.	0.9	13
60	Curcumin - The Nutraceutical With Pleiotropic Effects? Which Cardiometabolic Subjects Might Benefit the Most?. <i>Frontiers in Nutrition</i> , 2022, 9, .	3.7	12
61	Colchicine and Cardiovascular Outcomes: a Critical Appraisal of Recent Studies. <i>Current Atherosclerosis Reports</i> , 2021, 23, 32.	4.8	11
62	Extreme cardiovascular risk – do we need a new risk category?. <i>European Heart Journal</i> , 2022, 43, 1784-1786.	2.2	11
63	Activation of Î <sup>2</sup> -adrenoceptors mimics preconditioning of rat-isolated atria and ventricles against ischaemic contractile dysfunction. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2008, 378, 589-597.	3.0	10
64	Lecturing: A lost art. <i>Currents in Pharmacy Teaching and Learning</i> , 2012, 4, 72-76.	1.0	10
65	Clinical Features of Familial Hypercholesterolemia in Children and Adults in EAS-FHSC Regional Center for Rare Diseases in Poland. <i>Journal of Clinical Medicine</i> , 2021, 10, 4302.	2.4	10
66	Sunday 28 August 2016. <i>European Heart Journal</i> , 2016, 37, 191-598.	2.2	9
67	Genetic testing in familial hypercholesterolaemia: What does it add?. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 105-106.	1.8	9
68	Epigenetic control of atherosclerosis via DNA methylation: A new therapeutic target?. <i>Life Sciences</i> , 2020, 253, 117682.	4.3	9
69	The Differences in the Prevalence of Cardiovascular Disease, Its Risk Factors, and Achievement of Therapeutic Goals among Urban and Rural Primary Care Patients in Poland: Results from the LIPIDOGRAM 2015 Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 5656.	2.4	9
70	Nutraceuticals for the Control of Dyslipidaemias in Clinical Practice. <i>Nutrients</i> , 2021, 13, 2957.	4.1	9
71	CRISPR Gene Editing in Lipid Disorders and Atherosclerosis: Mechanisms and Opportunities. <i>Metabolites</i> , 2021, 11, 857.	2.9	8
72	Recent advancements in liposome-based strategies for effective drug delivery to the brain. <i>Current Medicinal Chemistry</i> , 2020, 28, 4152-4171.	2.4	7

#	ARTICLE	IF	CITATIONS
73	Monday 29 August 2016. <i>European Heart Journal</i> , 2016, 37, 599-983.	2.2	6
74	Exploring pharmacists's™ views surrounding conscientious objection to abortion and implications in practice. <i>International Journal of Pharmacy Practice</i> , 2021, 29, 258-264.	0.6	6
75	D-003 ( <i>Saccharum officinarum</i> ): The forgotten lipid-lowering agent. <i>Pharmacological Research</i> , 2016, 114, 42-46.	7.1	5
76	Challenges and Opportunities on Lipid Metabolism Disorders Diagnosis and Therapy: Novel Insights and Future Perspective. <i>Metabolites</i> , 2021, 11, 611.	2.9	5
77	Cellular senescence, telomeres, and cardiovascular risk in familial hypercholesterolaemia. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 718-720.	1.8	5
78	Analysis of the impact of sex and age on the variation in the prevalence of antinuclear autoantibodies in Polish population: a nationwide observational, cross-sectional study. <i>Rheumatology International</i> , 2022, 42, 261-271.	3.0	5
79	220â€¦ <i>Daphnia magna</i> as a model for quantifying chaos in cardiac arrhythmia. <i>Heart</i> , 2017, 103, A143.2-A143.	2.9	4
80	Associations between the lipid profile and the development of hypertension in young individuals â€“ the preliminary study. <i>Archives of Medical Science</i> , 2019, 18, 25-35.	0.9	4
81	Lifetime serum concentration of 25-hydroxyvitamin D 25(OH) is associated with hand grip strengths: insight from a Mendelian randomisation. <i>Age and Ageing</i> , 2022, 51, .	1.6	4
82	<i>Autonomic & Autacoid Pharmacology</i>: past, present and future. <i>Autonomic and Autacoid Pharmacology</i> , 2015, 35, 45-45.	0.5	3
83	Comparison of LDL-C calculation by friedewald and martin/hopkins methods in 12,243 adults from the United States of America. <i>European Heart Journal</i> , 2020, 41, .	2.2	3
84	The management of asthma in adult patients in the community pharmacy setting: Literature review. <i>Research in Social and Administrative Pharmacy</i> , 2021, 17, 1893-1906.	3.0	3
85	Vitamin D and SAMS. <i>Contemporary Cardiology</i> , 2020, , 121-128.	0.1	3
86	The prevalence of statin intolerance worldwide: a systematic review and meta-analysis with 4,143,517 patients. <i>European Heart Journal</i> , 2021, 42, .	2.2	3
87	Supermarket/Hypermarket Opportunistic Screening for Atrial Fibrillation (SHOPS-AF): A Mixed Methods Feasibility Study Protocol. <i>Journal of Personalized Medicine</i> , 2022, 12, 578.	2.5	3
88	Effects of hypoxia on the vasodilator activity of nifedipine and evidence of secondary pharmacological properties. <i>European Journal of Pharmacology</i> , 2006, 536, 279-286.	3.5	2
89	Synthesis of antagonists of muscarinic (M3) receptors. <i>Collection of Czechoslovak Chemical Communications</i> , 2011, 76, 781-801.	1.0	2
90	Warfarin Therapy and Improved Anticoagulation Control by Patient Self-Management. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1550-1552.	3.4	2

#	ARTICLE	IF	CITATIONS
91	Spotlight Commentary: What's new in lipid-lowering pharmacology? Integrating basic and clinical research to improve patient outcomes. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 2111-2113.	2.4	2
92	Serum antinuclear autoantibodies are associated with measures of oxidative stress and lifestyle factors: analysis of LIPIDOGram2015 and LIPIDOGEn2015 studies. <i>Archives of Medical Science</i> , 2023, 19, 1214-1227.	0.9	2
93	Secondary Stroke Prevention in Polish Adults: Results from the LIPIDOGram2015 Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 4472.	2.4	2
94	Warfarin—Is Self-Care the Best Care?. <i>Thrombosis and Haemostasis</i> , 2022, 122, 471-474.	3.4	2
95	Protective role of Î²2- and Î²3-adrenoceptors at reperfusion in isolated rat heart. <i>Journal of Molecular and Cellular Cardiology</i> , 2008, 44, 719.	1.9	1
96	Autonomic & Autacoid Pharmacology 2016: The year in review. <i>Autonomic and Autacoid Pharmacology</i> , 2016, 36, 27-27.	0.5	1
97	P5086Associations between very low concentrations of LDL-Cholesterol, hsCRP and health outcomes in the Reasons for Geographical and Racial Differences in Stroke (REGARDS) study. <i>European Heart Journal</i> , 2018, 39, .	2.2	1
98	Vernakalant hydrochloride for the treatment of atrial fibrillation: evaluation of its place in clinical practice. <i>Future Cardiology</i> , 2020, 16, 585-595.	1.2	1
99	Nutraceuticals for the Control of Dyslipidaemias in Clinical Practice. <i>Nutrients</i> , 2021, 13, .	4.1	1
100	Relationship Between Anti-DFS70 Autoantibodies and Oxidative Stress. <i>Biomarker Insights</i> , 2022, 17, 117727192110667.	2.5	1
101	Homozygous familial hypercholesterolaemia: shedding new light on a rare but deadly condition. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 815-816.	1.8	1
102	Incense — A problematic method of drug-delivery. <i>Medical Hypotheses</i> , 2009, 72, 482.	1.5	0
103	Autonomic and Autacoid Pharmacology: Goodbye and thank you. <i>Autonomic and Autacoid Pharmacology</i> , 2017, 37, 51-51.	0.5	0
104	P627Associations between very low concentrations of LDL-cholesterol and health outcomes in the reasons for geographical and racial differences in stroke (REGARDS) Study. <i>European Heart Journal</i> , 2017, 38, .	2.2	0
105	3104Associations between cardiovascular disease, cancer and very low hdl cholesterol in the reasons for geographical and racial differences in stroke (REGARDS) study. <i>European Heart Journal</i> , 2017, 38, .	2.2	0
106	3100Effects of morning versus evening statin therapy on lipid profile: a systematic review and meta-analysis. <i>European Heart Journal</i> , 2017, 38, .	2.2	0
107	P3836The prognostic accuracy of bleeding risk prediction scores in patients with atrial fibrillation: a systematic review and meta-analysis. <i>European Heart Journal</i> , 2018, 39, .	2.2	0
108	Bacterial lipopolysaccharide—Stoking the fire of residual risk?. <i>Trends in Cardiovascular Medicine</i> , 2021, , .	4.9	0

#	ARTICLE	IF	CITATIONS
109	Lipoprotein(a) and the risk of atrial fibrillation “ is there a link. Heart Beat Journal, 2017, 2, 49-50.	0.2	0
110	Management of Statin Intolerance. Contemporary Cardiology, 2021, , 207-218.	0.1	0
111	Assessment of asthma management in adult patients: A retrospective case-note review in a general practice. British Journal of Pharmacy, 2022, 7, .	0.3	0